Title: Bladder CancerCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 5/1/2018 12:00:00 AM

Related Links:

ConclusionThe combination of GEM plus TPL showed significantly enhanced anticancer effects compared to those of GEM or TPL alone.

ConclusionNotch signaling pathway regulators do not have the same activity within the different subtypes of bladder cancer and they can be divided into two groups that behave inversely. We showed for the first time that NOTCH3 does not have the same activity within bladder cancer categories and subtypes.Graphical abstract

Source: IRBMCategory: Biomedical Engineering Source Type: research

BLADDER cancer symptoms are triggered when its cells start dividing uncontrollably. Britons aren ’t always checking for signs. Watch out for this symptom of bladder and kidney cancer that only 16 per cent of Britons check for.

Authors: Matsuo K, Machida H, Mariani A, Mandelbaum RS, Glaser GE, Gostout BS, Roman LD, Wright JD
OBJECTIVE: To examine the trends and survival for women with early-stage epithelial ovarian cancer who underwent adequate lymphadenectomy during surgical treatment.
METHODS: This is a retrospective observational study examining the Surveillance, Epidemiology, End Results program between 1988 and 2013. We evaluated 21,537 cases of stage I-II epithelial ovarian cancer including serous (n=7,466), clear cell (n=6,903), mucinous (n=4,066), and endometrioid (n=3,102) histology. A time-trend analysis of the prop…

ConclusionsOur results support the feasibility of clinically relevant integrative bladder cancer profiling and challenge the intrinsic nature of expression subtypes in histologically diverse bladder cancers.Patient summaryA targeted RNA sequencing assay is capable of assessing gene expression-based subtypes in individual components of clinical bladder cancer tissue specimens. Different histological components of the same tumor may yield divergent expression profiles, suggesting that expression-based subtypes should be interpreted with caution in heterogeneous cancers.

Source: European UrologyCategory: Urology & Nephrology Source Type: research

ConclusionHBV infection is a risk factor for diverse extra-hepatic cancers in adolescents and 20s.

Conclusion: Lower expression of miR-374a is associated with poor prognosis and miR-374a improves tumor biological behavior in bladder cancer cells, suggesting that miR-374a might be a novel small-molecule therapeutic target.Cell Physiol Biochem 2018;48:815 –826

AbstractPurposeTo review the United States  National Cancer Database (NCDB) from 2004 to 2015 and analyze survival outcomes of invasive non-urachal adenocarcinoma based on treatment modality.MethodsThe NCDB 2004 –2015 bladder dataset was queried for adenocarcinoma histology, excluding urachal variant, and limited to patients with clinical stage T2–T4 disease. Treatment modality was categorized as no treatment, cystectomy (partial or radical), external beam radiation therapy (EBRT), or EBRT plus cystecto my. Our primary outcome was overall survival. Cox regression (CR) and Kaplan–Meier (KM) analysis w…

Radiotherapy is widely used as a curative treatment for pelvic malignancies. The location of these organs leads to unavoidable exposure of the bladder, urethra and distal ureters to radiation and may cause subsequent development of radiation cystitis, fistulas, strictures and secondary malignancy. As cancer survival improves, an ever-increasing number of patients are living with the long-term complications of radiotherapy. Symptoms are not only debilitating for the patient but also pose a treatment challenge to the urologist.

Source: UrologyCategory: Urology & Nephrology Authors: Source Type: research

Radical cystectomy (RC) associated with pelvic lymph node dissection (PLND) is the most common local therapy in the management of non-metastatic muscle invasive bladder cancer (MIBC) [1]. More recently, peri-operative chemotherapy has been the subject of study in randomized trials and meta-analyses that have led to controversial results depending on the analyzed end-point [2]. In the SWOG-Intergroup phase 3 trial, patients were randomly assigned three cycles of methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) or no neo-adjuvant chemotherapy.

Source: Cancer Treatment ReviewsCategory: Cancer & Oncology Authors: Tags: Systematic or Meta-analysis Studies Source Type: research

Source link


Please enter your comment!
Please enter your name here